Chengdu's Hinova Pharma Raises $147 Million for Novel Prostate, Gout Drugs
October 08, 2020 at 07:43 AM EDT
Hinova Pharmaceuticals, a Chengdu innovative drug company, closed a $147 million Series C round. The company said it would use the proceeds to conduct multi-center clinical trials and commercialize its drug candidates in China and internationally. Founded in 2013, Hinova has built a portfolio of nine drug candidates including HC-1119, a novel androgen receptor antagonist in Phase III trials for metastatic castration-resistant prostate cancer (mCRPC). Its other lead drug targets gout. More details.... Share this with colleagues: // //
